Genetic analyses in a cohort of children with pulmonary hypertension

Marilyne Levy1, Mélanie Eyries2, Isabelle Szezepanski3

  • 1Université Paris Descartes, Sorbonne Paris Cité, Paris, France M3C-Unité Médico-Chirugicale de Cardiologie Pédiatrique, Hôpital Necker-Enfants Malades, AP-HP, Paris, France marilyne.levy@ue3c.fr.

Insights

Germline mutations are present in childhood pulmonary hypertension (PH), with carriers showing more severe disease at diagnosis. Genetic analysis revealed specific gene mutations, including ACVRL1 and TBX4, in paediatric PH cases.

Area of Science:

  • Genetics
  • Pediatrics
  • Cardiology

Background:

  • Germline mutations in pediatric pulmonary hypertension (PH) are not well-documented.
  • Understanding genetic contributions is crucial for diagnosing and managing childhood PH.

Purpose of the Study:

  • To determine the frequency of mutations in PH-associated genes within a pediatric cohort.
  • To describe the clinical features of mutation carriers in pediatric PH.

Main Methods:

  • Genetic analysis of 66 pediatric PH index cases, including idiopathic pulmonary arterial hypertension (IPAH), familial PAH (FPAH), pulmonary veno-occlusive disease (PVOD), and PAH with congenital heart disease (APAH-CHD).
  • Sequencing of key PH genes such as BMPR2, ACVRL1, TBX4, and EIF2AK4.

Main Results:

  • No mutations were identified in the APAH-CHD group.
  • Twelve mutations were found in 40 children with IPAH or FPAH (BMPR2: 5, ACVRL1: 4, TBX4: 3).
  • Two of three PVOD cases carried an EIF2AK4 mutation. Mutation carriers presented with more severe disease at diagnosis, requiring aggressive therapy.

Conclusions:

  • The genetic landscape of pediatric PAH may differ from adult PAH, with a potential enrichment of ACVRL1 and TBX4 mutations.
  • Childhood-onset PH with identified mutations presents more severely at diagnosis but has a similar outcome to non-carriers.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
766
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.5K
Pedigree Analysis01:35

Pedigree Analysis

Overview
90.4K
Pedigree Analysis01:35

Pedigree Analysis

18.9K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94